Codexis, Inc. (CDXS): Price and Financial Metrics

Codexis, Inc. (CDXS): $4.04

0.18 (+4.66%)

POWR Rating

Component Grades













Add CDXS to Watchlist
Sign Up

Industry: Biotech



in industry


  • CDXS scores best on the Quality dimension, with a Quality rank ahead of 79.6% of US stocks.
  • CDXS's strongest trending metric is Quality; it's been moving up over the last 178 days.
  • CDXS ranks lowest in Stability; there it ranks in the 21st percentile.

CDXS Stock Summary

  • Of note is the ratio of CODEXIS INC's sales and general administrative expense to its total operating expenses; merely 18.85% of US stocks have a lower such ratio.
  • Over the past twelve months, CDXS has reported earnings growth of 57.97%, putting it ahead of 79.48% of US stocks in our set.
  • The volatility of CODEXIS INC's share price is greater than that of 84.63% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to CODEXIS INC, a group of peers worth examining would be VERU, SAGE, PXLW, MRNS, and RMBS.
  • CDXS's SEC filings can be seen here. And to visit CODEXIS INC's official web site, go to

CDXS Valuation Summary

  • CDXS's EV/EBIT ratio is -5.5; this is 183.97% lower than that of the median Healthcare stock.
  • CDXS's price/sales ratio has moved down 3.5 over the prior 157 months.

Below are key valuation metrics over time for CDXS.

Stock Date P/S P/B P/E EV/EBIT
CDXS 2023-03-17 1.9 1.8 -7.6 -5.5
CDXS 2023-03-16 2.0 1.9 -8.1 -6.0
CDXS 2023-03-15 2.0 1.9 -8.2 -6.1
CDXS 2023-03-14 2.0 1.9 -8.3 -6.2
CDXS 2023-03-13 2.0 1.9 -8.3 -6.2
CDXS 2023-03-10 2.0 1.9 -8.1 -6.0

CDXS Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 19.11%.
  • Its 2 year net cashflow from operations growth rate is now at -70.77%.
  • Its 5 year net cashflow from operations growth rate is now at -70.53%.
CDXS's revenue has moved up $89,778,000 over the prior 70 months.

The table below shows CDXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 138.59 11.284 -33.592
2022-09-30 132.717 7.027 -31.178
2022-06-30 135.016 -12.899 -18.942
2022-03-31 122.063 -19.013 -20.567
2021-12-31 104.754 -14.267 -21.279
2021-09-30 101.287 -16.419 -15.009

CDXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXS has a Quality Grade of C, ranking ahead of 53.6% of graded US stocks.
  • CDXS's asset turnover comes in at 0.423 -- ranking 65th of 89 Chemicals stocks.
  • NGVT, GPP, and IFF are the stocks whose asset turnover ratios are most correlated with CDXS.

The table below shows CDXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.423 0.782 -0.333
2021-03-31 0.406 0.787 -0.370
2020-12-31 0.424 0.801 -0.359
2020-09-30 0.461 0.831 -0.313
2020-06-30 0.479 0.819 -0.220
2020-03-31 0.457 0.796 -0.237

CDXS Price Target

For more insight on analysts targets of CDXS, see our CDXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.50 Average Broker Recommendation 1.31 (Strong Buy)

CDXS Stock Price Chart Interactive Chart >

Price chart for CDXS

CDXS Price/Volume Stats

Current price $4.04 52-week high $22.22
Prev. close $3.86 52-week low $3.79
Day low $3.93 Volume 420,574
Day high $4.07 Avg. volume 656,464
50-day MA $5.47 Dividend yield N/A
200-day MA $6.71 Market Cap 266.43M

Codexis, Inc. (CDXS) Company Bio

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.

CDXS Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream

Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as induceme

Yahoo | March 9, 2023

Codexis to Participate in Cowen 43rd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo

Yahoo | February 27, 2023

These Analysts Think Codexis, Inc.'s (NASDAQ:CDXS) Sales Are Under Threat

One thing we could say about the analysts on Codexis, Inc. ( NASDAQ:CDXS ) - they aren't optimistic, having just made a...

Yahoo | February 27, 2023

Q4 2022 Codexis Inc Earnings Call

Q4 2022 Codexis Inc Earnings Call

Yahoo | February 24, 2023

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2023

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo -29.49%
3-mo -15.66%
6-mo -34.73%
1-year -79.80%
3-year -55.01%
5-year -65.02%
YTD -13.30%
2022 -85.10%
2021 43.24%
2020 36.52%
2019 -4.25%
2018 100.00%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.836 seconds.